Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

This study has been completed.
Sponsor:
Information provided by:
Stealth Peptides Inc.
ClinicalTrials.gov Identifier:
NCT01115920
First received: April 30, 2010
Last updated: November 17, 2010
Last verified: November 2010
  Purpose

This is the first study of MTP-131 (Bendavia™) in humans. The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single intravenous infusion doses of MTP-131.


Condition Intervention Phase
Healthy
Drug: MTP-131 (Bendavia™)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I Study in Healthy Male and Healthy Female Subjects to Characterize the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusion of MTP-131 (Bendavia™) Using a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design

Further study details as provided by Stealth Peptides Inc.:

Primary Outcome Measures:
  • Treatment emergent adverse events in treatment group versus placebo group [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
    Safety assessments including vital signs, physical exam,12-lead ECG, serum chemistry, hematology, and urinalysis will be collected the day prior to and for 7 days following study drug infusion. These parameters will be assessed for clinically significant abnormalities.


Secondary Outcome Measures:
  • Pharmacokinetics of MTP-131 including Css, Cmax, tmax, t½, AUC and dose proportionality. [ Time Frame: Pre-infusion through 32 hours post infusion ] [ Designated as safety issue: No ]
    Css (plasma steady state concentration), Cmax (observed peak plasma concentration), tmax (time of observed peak), AUC0-t (area under the plasma concentration time curve from time zero to the last quantifiable timepoint), AUC0-∞ (area under the plasma concentration time curve from time zero to infinity), λz (terminal [or elimination rate] phase rate constant), t½ (terminal half-life), CL (plasma clearance) and Vss (volume of distribution at steady state) will be determined for MTP-131. Ae (amount excreted in the urine) and CLr (renal clearance) may also be evaluated.


Enrollment: 40
Study Start Date: May 2010
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Cohort 1, Dose 0.010 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
Drug: MTP-131 (Bendavia™)
Single 4 hour intravenous infusion
Experimental: Arm 2
Cohort 2, Dose 0.025 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
Drug: MTP-131 (Bendavia™)
Single 4 hour intravenous infusion
Experimental: Arm 3
Cohort 3, Dose 0.050 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
Drug: MTP-131 (Bendavia™)
Single 4 hour intravenous infusion
Experimental: Arm 4
Cohort 4, Dose 0.100 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
Drug: MTP-131 (Bendavia™)
Single 4 hour intravenous infusion
Experimental: Arm 5
Cohort 5, Dose 0.250 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
Drug: MTP-131 (Bendavia™)
Single 4 hour intravenous infusion

Detailed Description:

The primary objective of the study is to evaluate the safety and tolerability of MTP-131 in healthy volunteers following a single intravenous infusion. The secondary objective is to evaluate the pharmacokinetics of MTP-131. This is a double-blind, placebo-controlled, randomized trial. A total of 40 eligible subjects will be enrolled and randomized in a 3:1 active to placebo ratio for a total of 5 treatment groups of 8 volunteers. As far as is logistically possible, each treatment group will have similar numbers of male and female volunteers. After the last subject for each cohort has completed the day 3 clinical assessment and no stopping rules have been met according to Safety Review Board decision, the next cohort will commence.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult males or females age ≥18 years of age with signed informed consent.
  • Women who are not post-menopausal or surgically sterile must have a negative serum pregnancy test at screening and within 24 hours of treatment and who agree to use effective contraception for 30 days following the study.

Exclusion Criteria:

  • Clinically significant laboratory abnormalities,
  • Clinically significant abnormalities on physical examination,
  • BMI of less than 18 kg/m2 or greater than 32 kg/m2,
  • Any disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems,
  • History of seizures or epilepsy,
  • History of serious mental illness,
  • Participant in unrelated research involving investigational product within 30 days before planned date of drug administration,
  • Positive serology for HIV 1, HIV 2, HBsAg, or HCV,
  • Fever greater than 37.5°C at the time of planned dosing,
  • Suspicion of or recent history of alcohol or substance abuse,
  • Donated blood or blood products within the past 30 days,
  • Women who are pregnant or breastfeeding,
  • Employee or family member of the investigational site, and
  • Subjects who currently smoke cigarettes, cigars, pipes or chew tobacco products,
  • Subjects who are either unwilling to agree to refrain from use or found to be using:

    1. Alcohol, caffeine, xanthine-containing food or beverages, nicotine products and over-the-counter medications with the exception of Tylenol from 24 hours prior to dosing and throughout the confinement period
    2. Prescription medications from 14 days prior to and 7 days post treatment
    3. Oral contraceptives without concomitant use of double-barrier contraceptives (condom, diaphragm with spermicide) for a period of 7 days prior to and 30 days post treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01115920

Locations
United States, Florida
Clinical Pharmacology of Miami, Inc.
Miami, Florida, United States, 33014-3616
Sponsors and Collaborators
Stealth Peptides Inc.
Investigators
Principal Investigator: Kenneth Lasseter, MD Clinical Pharmacology of Miami, Inc.
  More Information

No publications provided

Responsible Party: Richard Straube, MD, Chief Medical Officer, Stealth Peptides, Inc.
ClinicalTrials.gov Identifier: NCT01115920     History of Changes
Other Study ID Numbers: SPIRI-101
Study First Received: April 30, 2010
Last Updated: November 17, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Stealth Peptides Inc.:
Drug Safety
Clinical Trial, Phase I
Nontherapeutic Human Experimentation
Heading Pharmacokinetics
Phase I Safety and Tolerability

ClinicalTrials.gov processed this record on September 18, 2014